Bevasiranib Drug Asset Due Diligence Report 2026

This Bevasiranib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

153

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Bevasiranib can convert its siRNA profile and VEGF-A biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Bevasiranib (query alias: Bevasiranib)
Modality / target	siRNA; VEGF-A; VEGF-A inhibitors, RNAi
Highest global status	Phase 2
Originator	OPKO Health, Inc.
Active developers	Robert Wood Johnson Medical School

The MCP disease footprint includes Diabetic macular oedema. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT00722384	Phase 1	Completed	15	Primary endpoint not disclosed in English source
NCT00557791	Phase 3	Withdrawn	0	Primary endpoint not disclosed in English source
NCT00499590	Phase 3	Terminated	338	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).

Phase 3; n=338; evaluation: Not stated in English source. Reported fields: Other (Not Including Serious) Adverse Events = 85 Pts ; Other (Not Including Serious) Adverse Events = 96 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Bevasiranib addresses Diabetic macular oedema. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—siRNA—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 153 matched transaction record(s) under the scope “target-level comparable: VEGF-A.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: VEGF-A records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-08-19	Senju Pharmaceutical had entered into an agreement to commercialize Sam Chun Dang Pharm ' SCD-411 for glaucoma	Approved	Financial terms not disclosed
2026-07-29	Mabwell Established a Licensing and Commercialization Agreement of Aflibercept Biosimilar for GCC Market	NDA/BLA	Financial terms not disclosed
2026-07-09	Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in Canada	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination of a VEGF inhibitor and a complement pathway inhibitor for treating ocular disorders”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical compositions for treatment of central nervous system disorders”. The milestone feed surfaced a patent-application signal described as “Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO